Elan chairman worked for GSK in high positions.Even consults now with top mgmt.
With GSK losing its patents in USA for Lovaza and now AZN buying Omthera-- GSK must be reviewing their options. For this reason,I take Elan interest in Amarin seriously.
I think GSK might step in at some point -if they could buy Amarin for 15$/share.
GSK paid huge amt. for Reliant and they know this business well.
GSK paid 1.65 bil.$ in 2005 for use of exclusive rights for 9 years.That is far more than AZN paid for Omthera.
I think GSK feels threatened with AZN purchase.They have couple of options:
Do nothing and lose Lovaza sales in 2015--roughly 900 mil.$.
Buy Amarin now--when price is down. 100 to 120% premium --15$/share might get them majority control.